Neonatal Sepsis And Antibiotic Sensitivity Patterns At A South African Tertiary Nursery – Evolution Over A 15 Year Period by Naidoo, Nayestha
  
NEONATAL SEPSIS AND ANTIBIOTIC SENSITIVITY 
PATTERNS AT A SOUTH AFRICAN TERTIARY 
NURSERY – EVOLUTION OVER A 15 YEAR PERIOD 
 
Dr Nayestha Naidoo 
Paediatric Registrar 
University of Cape Town 
NDXNAY001 
 
 
Supervised by: Professor Michael Harrison 
Head of Department 
Groote Schuur Department of Neonatology 
Co-Supervisor : Professor Alan Horn 
Groote Schuur Department of Neonates 
 
Submitted in fulfilment of the requirements of the degree 
MMed (Paediatrics) 
To the Faculty of Health Sciences 
University of Cape Town 
 
Date of submission: 03 October 2019 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  2 
TABLE OF CONTENTS 
 
Declaration        3 
Abstract        4 
Acknowledgements and Contributions    6 
List of tables        7 
List of Figures        7 
Abbreviations        8 
Chapter 1 : Introduction and Literature review   9 
Chapter 2 : Publication Ready Manuscript       23   
Appendix A: Instruction to authors (SAMJ)    36 
Appendix B: Ethics approval      42 
Appendix C: Study Deviation     43 
Appendix D: Department research approval    45 
  
 
 
 
 
 
 
 
 
 
 
 
 
DECLARATION 
I, Dr Nayestha Naidoo, hereby declare that the work on which this dissertation is 
based is my original work (except where acknowledgements indicate otherwise) and 
that neither the whole work nor any part of it has been, is being, or is to be submitted 
for another degree in this or any other university.  
I empower the university to reproduce for the purpose of research either the whole or 
any portion of the contents in any manner whatsoever.  
Signature: 
Date: 03 October 2019 
3 
  4 
ABSTRACT 
 
Background 
Neonatal infection is an important cause of morbidity and mortality in babies. The 
causative pathogens and their antibiotic susceptibility patterns should be monitored so 
that treatment regimens can be adjusted to maintain efficacy and avoid selection of 
resistant organisms. 
Objectives 
To compare the incidence of culture positive neonatal sepsis; and to  describe the 
pathogens and antibiotic resistance profiles for significant organsims over a 15-year 
period in a tertiary nursery in Cape Town. 
Methods 
Retrospective blood culture data for 12 months were collected at three time points 
over a 15-year period. Blood cultures from 2004, 2013 and 2017 were analysed. All 
neonates with growth on blood cultures were included.  
Results 
During 2004 a total of 817 (43.3% of total admissions) blood cultures were taken, 171 
(9.1% of total admissions) were culture positive. The most common invasive 
organisms were Klebsiella pneumoniae (31.8% of invasive organisms), S.aureus 
(26.1%) and enterococcus species (7.3%). There were 102 contaminants (12.5% of 
total cultures) of which 7.8% were due to Coagulase-negative Staphylococcus 
(CONS).  
In 2013 a total of 1070 (46.8% of total admissions) blood cultures were taken, 124 
(5.4% of total admissions) were culture positive. Common invasive organisms were 
Klebsiella pneumoniae (53.8% of invasive organisms), E. coli (12.8%) and S. aureus 
(10.3% ). Forty-six  blood cultures were deemed contaminated (4.3% of all cultures) 
and of these 2.1% were due to CONS. 
In 2017, there were 581 blood cultures taken (26.5% of total admissions), 56 were 
culture positive (2.6% of total admissions). Commonly occuring invasive organisms 
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were Klebsiella pneumoniae (32.4% of invasive organisms), Group B streptococcus 
(16.2%) and Acinetobacter (13.5%). Twenty-nine blood cultures were considered 
contaminated (5.6% of cultures) of which 1.7% were CONS. 
The gram-negative organisms showed an increasing resistance to penicillin, ampicillin 
and  aminoglycosides but remained sensitive to carbapenems. 
Conclusions 
The initial reduction in positive blood cultures from 2004 to 2013 was primarily due 
to the reduction of contaminants, probably reflecting improved blood sampling 
techniques. The large reduction in Gram-negative organisms from 2013 to 2017 
suggests improved infection control measures , but gram-negative organisms 
remained prominent in all three cohorts. Emergence of resistant organisms is 
concerning and in keeping with other nurseries worldwide. These data illustrate the 
need for antibiotic stewardship, infection control measures and ongoing surveillance. 
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CHAPTER ONE –  LITERATURE REVIEW 
 
INTRODUCTION 
Neonates are vulnerable hosts for infection caused by pathogenic organisms such as 
bacteria, fungi or viruses. This may be because both term and preterm infants have 
innate immunity that is unable to respond adequately to infection. They exhibit both 
qualitative and quantitative defects in their complement system.(1) Preterm infants 
have much lower concentrations of immunoglobulins.(1) In addition, their immature 
skin forms a weak barrier against the environment. Admission to hospital can lead to 
multiple procedures being carried out which can place them at risk for acquiring 
infection.  It is the sum of all these variables that lead them to succumb easily to 
infection. 
According to the World Health Organisation (WHO), about 5 million neonates die 
annually.(2-4) Neonatal death is defined as a neonate dying within the first 28days of 
life.(4)  Infection is one of the most important causes of neonatal death(4) and three 
quarters of all newborn deaths occurs in the first week of life.(5)  
Neonatal sepsis is defined as a clinical syndrome in an infant 28 days of life or 
younger manifested by systemic signs of infection and isolation of a bacterial 
pathogen from the bloodstream.(6) A blood culture is considered the gold standard 
for diagnosis of sepsis.  Once sepsis is diagnosed, it may be further categorised as 
early onset or late-onset infection.(1)  
Early onset neonatal sepsis (EONS) is defined as a neonate who has clinical signs 
of infection within 72 hours of birth. Early onset infection is assumed to occur as a 
result of the infant acquiring the infection before or during delivery. Most early 
onset sepsis presents within the first 24 hours of life.(6) Clinical signs of infection 
poor feeding, lethargy, respiratory distress, apnea, cyanosis, temperature 
instability, vomiting, abdominal distension, diarrhoea, lethargy, convulsion, 
hypotonia, and irritability.(7) While evidence is lacking, the choice of antibiotics 
for suspected early neonatal sepsis may be guided by the spectrum of organisms 
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from microbiological surveillance cultures, for example the prevalence of Group B 
Streptococcus and Gram negative organisms.(8) 
Late onset neonatal sepsis (LONS) is defined as a neonate who has clinical signs of 
infection after 72hours of life and is usually acquired in the nursery or out in the 
community.(1)  Late-onset sepsis (LOS) acquired in hospital can be a complication 
of extreme prematurity.(9) Very late onset neonatal sepsis(VLONS) are infections 
occurring after 1month of life.(1) More resistant organisms are expected from 
hospital acquired late sepsis when compared to vertically transmitted, community 
acquired, early sepsis.(10)  Studies have reported rates of hospital-acquired 
neonatal infections that are 3–20 times more common in resource- poor than in 
resource-rich countries.(11) 
The organisms responsible for neonatal sepsis differ across countries and with the 
timing of onset of infection.(12) In addition to this, one organism may over time 
replace another as the leading cause of neonatal sepsis in a particular nursery or 
geographical region. This is further compounded by the fact that local drug 
resistance profiles change over time, thereby complicating treatment regimens.(13) 
Overuse of broad spectrum antibiotics is what drives emergence of resistance but 
surveillance and antibiotic stewardship helps prevent inappropriate antibiotic use.  In 
South Africa the surveillance programme as outlined by the department of health 
focuses on the ESKAPE pathogens (Enterococcus faecium/faecalis, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, 
and Escherichia coli species) and Candida within blood cultures only, as they are the 
leading causes of nosocomial infections throughout the world.(14)  
Early and efficient diagnosis of neonatal sepsis remains nuanced as clinical 
manifestations of infection vary greatly. This necessitates the use of an empiric 
antibiotic therapy approach upon suspicion of sepsis.(13) A periodic survey of the 
causes of sepsis and their antibiotic sensitivity patterns is essential in the design of 
effective infection control programmes and in guiding empirical antibiotic 
therapy.(3, 15, 16) 
The Groote Schuur Nursery is a tertiary unit that admits and manages babies of 
varying weights and maturity. The Groote Schuur Hospital (GSH) Neonatal Nursery, 
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with its 75-bed capacity, admits over 2000 neonates per year. Over 500 of these are 
Very Low Birth Weight  (VLBW) infants - neonates weighing less than 1500g. The 
nursery offers Intensive Care facilities, with 8 beds for conventional and oscillatory 
ventilation, 12 beds with non-invasive ventilatory facilities. 
The GSH Neonatal Unit policy for suspected sepsis is based on a consistent and 
disciplined approach to antibiotic usage to provide optimal broad spectrum cover 
while being cognisant about limiting the emergence of resistant organisms.(17) 
Objectives 
The objectives of this literature review were: 
I) to describe the changing etiology of neonatal sepsis globally; and  
ii) to describe the variation in antibiotic susceptibility patterns 
METHODS 
Search strategy 
An electronic search of the relevant literature was undertaken on 5 February 2018 and 
again on 5 June 2019 using the PubMed, Ebscohost and Cochrane databases. Medical 
Subject Headings (MeSH) were used in these searches. Filters were applied to include 
studies in humans, studies in children and studies published after 2000. All article 
types were included. Results were screened based on relevance of title and review of 
the abstract. Only articles available in full text in English were included. Full texts 
were downloaded via the UCT library website.  South African government protocols, 
WHO guidelines and textbooks about this topic were included in the search. 
Inclusion criteria 
 Human subjects 
 Patients enrolled in the neonatal period ie. first 28days of life 
 All patients with blood cultures taken 
 Full free text in English 
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Exclusion criteria 
 Samples other than blood cultures ie cerebrospinal fluid, pus swabs, ascitic or 
pleural taps 
 Patients enrolled beyond the neonatal period 
 Studies focusing on specific morbidity outcomes eg NEC , IVH etc 
 Studies focusing on specific antibiotic usage or single bacterial isolates 
 Studies before the year 2000 
 Studies focusing on maternal factors 
 Studies focusing on adjunctive diagnosis of sepsis ie. serum laboratory tests 
 Studies not in English 
RESULTS AND DISCUSSION 
The yield of the search is shown in figure 1 
 Figure 1: The process and yield of the literature search. 
 
Search 1 : Cochrane 
- Neonatal sepsis, 
antibiotic sensitivity
11
Search 2 :Pubmed -
Sepsis, Neonat*, early 
onset, late onset, 
Antibiotic 
susceptibility, 
resistance, 
contamination
38
Inclusion and 
exclusion criteria 
applied based on 
titles and duplicates 
excluded
30
Search 3 : Ebscohost 
- Neonatal sepsis, 
early onset, late 
onset, antibiotic 
sensitivity
43
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Thirty full text articles fulfilled the criteria stipulated above and were included. The 
geographic origins of the papers is shown in table 1.1. 
 
Table 1.1: Geographic origins of papers reviewed 
Country Number of papers 
United States of America 4 
Serbia 1 
South Asia 2 
India 4 
China 2 
Egypt 3 
Pakistan 1 
Bosnia 1 
Brazil 1 
Ghana 1 
Australia 1 
Nigeria 2 
Vietnam 1 
Turkey 1 
South Africa 3 
Tanzania 1 
Iran 1 
 
Risk factors for EONS 
Risk factors for EONS have been published from facilities in the developing 
countries, Nigeria and China, which are  capable of providing intensive neonatal care 
(ie ventilation and central lines) for their regions.(18, 19) Risk factors associated with 
EONS in these settings were : weight <1.5kg (Adjusted odds ratio (AOR) 3.3 (1.8-
5.9)), lower socioeconomic class (AOR 3.08 (1.86-5.11)), gestational age < 32weeks 
(AOR 6.18 (2.6 - 15)), maternal infection (AOR 2.25 (1.05-4.78)), maternal GBS 
colonization, prolonged labour and prolonged rupture of membranes (AOR 5.7 (3.2-
10.4)).(18, 19) 
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Micro-organism profile in EONS 
Early onset neonatal sepsis was prominent in neonatal units in the following 
developing countries that were capable of providing either secondary or tertiary 
neonatal intensive care: Nigeria,(19) China,(18) India,(20) (21) and Pakistan.(22) 
There were no articles from developed countries to compare as they did not fulfill 
selection criteria. The Gram positive organisms, CONS and S. aureus were dominant 
in 3 studies from Nigeria, India and China,(18-20) whilst the gram negative 
organisms E. coli, Klebsiella and Acinetobacter were dominant in two studies from 
India and Pakistan.(21, 22) None of the articles reviewed specific medical sequelae 
related to pathogens identified for EONS. The high prevalence of EONS noted  in 
these centres could possibly be attributed to perinatal events, vertical transmission 
from the maternal tract or early acquisition of pathogens from NICU or delivery 
rooms.(19, 21)  
Risk factors for LONS 
Three papers from developing and upper middle class countries; Tanzania, Brazil and 
Bosnia, highlighted risk factors associated with LONS.(23-25) These were prolonged 
rupture of membranes (p=0.0001), meconium stained liquor (p=0.0001), weight 
<1.5kg (Relative Risk (RR) 1.37 95% confidence interval (CI) 0.91-2.106), use of a 
central venous catheter (RR 3.44 95% CI 2.39-4.93), surgery (RR 2.03 95% CI 1.12-
3.7), mechanical ventilation (RR4.36 95% CI 3.05-6.23), 5minute APGAR<3 (RR 
2.45 95% CI 1.04-5.76) and gestational age < 28weeks.(23-25)  
Micro-organism profile in LONS 
Late onset neonatal sepsis was the prominent cause of neonatal sepsis in several 
papers from countries of variable financial status: Tanzania,(23) Vietnam,(26) 
Ghana,(27) Egypt,(28) Brasil,(24) South Africa,(13, 16) and Bosnia.(25) Ventilation 
could be offered in all these centres. The Gram-positive organisms; S. aureus, CONS 
and Enterococcus faecalis were dominant in Tanzania, Brasil, Bosnia, South Africa 
and Ghana.(13, 23-25, 27) The Gram negative organism; Klebsiella was dominant in 
another South African NICU(16) and fungi were responsible for LONS in a 
prospective cohort done in the largest neonatal unit in central Vietnam.(26) Gram 
negative organisms had a higher mortality rate as noted by Kayange et al 
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(p=0.0001).(23)  None of the articles reviewed specific medical sequelae related to 
the organisms responsible for LONS. 
Micro-organism profile in both early and late onset neonatal sepsis 
 
The gram positive organism, Group B Streptococcus (GBS) is a significant cause of 
neonatal sepsis (EONS and LONS). Although it was first identified in the early 
1960’s, maternal prophylaxis against this pathogen has only been implemented since 
the 1990’s. Currently there is a low prevalence of group B streptococci infection in 
Asia compared to a high incidence in high income countries such as the United States 
of America and England.(21, 29) S. aureus dominated in Sagamu, Nigeria and in a 
cross sectional study from Pune,India.(20, 23)   
 
Coagulase negative staphylococcus (CONS) is another important gram positive 
organism implicated in both early and late neonatal sepsis.(30) There are no definitive 
guidelines on classification of CONS as true sepsis or contaminant.(31) Coagulase 
negative staphylococcus was noted to cause sepsis amongst premature infants a 
prospective study done in a NICU between 2003 and 2010 in Turkey (32) and in a 
study done in a South Africa in a tertiary NICU between 2009 and 2010.(15) A study 
done in Houston, Texas was done to distinguish true CONS infection from 
contamination and they proved within their NICU that invasive CONS infection 
occurred among infants with birth weight <2000 g (p<0.001) and gestational age <34 
weeks (p<0.001).(33)  However, CONS may not be as virulent as gram negative 
organisms or fungi and so clinical significance using isolation from more than one 
blood culture from different sites in the same neonate(33) may be helpful in each case 
specifically.(34, 35)  
 
Gram negative organisms are also emerging as causing serious neonatal infections. 
E.coli, Klebsiella pneumoniae and Pseudomonas aeruginosa are such organisms found 
to cause both early and late sepsis.(13, 36) Gram negative organisms  (Klebsiella 
pneumonia, E.Coli, Acintetobacter, Serratia) dominated in Egypt(10) (7) and South 
Africa.(16) No prophylaxis or screening exists for these organisms, therefore prompt 
identification and treatment is necessary.  
Contamination 
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Contamination usually results from bacteria present in the environment or on the skin 
when sampling – it can increase NICU cost burden and falsely increase morbidity and 
mortality rates.(34)  Clinicians need to make a decision on whether an isolate is a 
contaminant or not to determine appropriate treatment. Raban et al suggest that the 
rates of both neonatal sepsis and contaminated blood cultures can be decreased by 
using the following interventions : written policies prioritising hand washing; a ‘bare-
below-elbows’ approach; a uniform blood culture technique; appropriate antibiotic 
use; and insertion and management of central lines according to a standardised 
protocol.(37) Video material was used to reinforce these techniques. By implementing 
the above, they reduced the level of neonatal sepsis (p=0.002) while also reducing 
contaminated blood cultures (p<0.001) within their unit.(34)  
 
Change in organisms in a single unit over time 
 
There were few papers that studied changing organisms in a particular unit over time. 
Two references briefly mention this – a Nigerian(19) and a South African(16) study. 
In Nigeria, a retrospective review was carried out on neonates receiving specialist 
care at a teaching hospital between Jan 2006 and December 2007 and a prospective 
review studied neonates between January to December 2008.(19) The authors found 
S. aureus to be commonest organism followed by Klebsiella pneumonia and E. coli. 
The data was compared with two earlier studies done in the last two decades. The 
commonest organism causing neonatal sepsis between 1987 – 1989 was S. aureus and 
Klebsiella was the most frequent organism between 1991- 1992.(19)  Lebea at al(16) 
retrospectively described organisms in their South African neonatal unit (within an 
academic hospital) from January to December 2012. Gram negative organisms 
dominated the sepsis profile in the most recent study(2012) but gram positive 
(particularly CONS) dominated in their study done in 2002.(16)  Both these studies 
confirm that organisms causing neonatal sepsis change over time and repeated 
surveillance is recommended within a specific institute.  
 
 
Antibiotic susceptibility patterns 
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Two Cochrane meta-analyses have addressed the issue of empiric antibiotic regimens 
for neonatal sepsis. Both included randomised control trials done in the 1980’s and 
early 1990’s comparing monotherapy versus dual therapy antibiotic treatment.(8, 31) 
Mtitimila et al in 2004(8) reviewed antibiotic regimens for suspected early onset 
neonatal infections – including RCT from two developed countries; and Gordon et al 
in 2005(31) reviewed antibiotic regimens for suspected late onset neonatal infections 
– including RCTs from developed and developing countries. Both concluded that 
there is no evidence to suggest that any antibiotic regimen may be better than any 
other in the treatment of presumed neonatal sepsis and more studies are needed to 
resolve this.(8, 31)  
 
Another Cochrane meta-analysis by Ungerer et al in 2004 (38) sought to seek answers 
about prophylactic versus selective antibiotics for asymptomatic term neonates born 
to mothers with risk factors for neonatal infection. The data they analysed came from 
two randomised control trials or quasi random methods of allocation – the trials were 
old, done in the 1970’s, one from South Africa and the other from Belgium and 
ultimately inconclusive to guide clinical practice. In the same article they highlight 
that a delay in initiating antibiotic treatment when it is needed may increase neonatal 
morbidity and mortality (RR not estimable) although prophylactic use of antibiotics 
may result in antibiotic treatment of many infants who are not infected (favours 
selective antibiotic use RR 5.66 [ 2.44, 13.14 ]). (38)  This further leads to 
complications of antibiotic therapy such as resistant infections and fungal 
infections.(38) 
 
Resistant organisms are emerging within neonatal units.(10, 21, 39) Antibiotic 
resistance, mainly driven by antibiotic misuse and overuse, is a global phenomenon 
but worse in low-middle income countries.(40) All medical units (including neonatal) 
are becoming more aware of this growing superbug problem. A meta-analysis done 
which reviewed 109 studies involving countries from South Asia found alarmingly 
high rates of resistance (55-88%) to recommended first line antibiotics(ampicillin and 
gentamycin).(29) In a prospective study reviewing 25 years of data in a tertiary NICU 
in Australia, it was found to be a safe practice to stop antibiotics after 48-72 hours if 
cultures were negative, however it did not prevent the development of resistant Gram-
negative organisms within their unit.(40) While awaiting the development of new 
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antibiotics, the development of multidrug resistant Gram negative bacteria is 
worrisome and highlights the need to preserve the antibiotics we have and use them 
appropriately.(41)  
 
Evidence of changing antibiotic susceptibility profiles can be seen in a retrospective 
review done by Ogunlesi et al from Nigeria.(19) In this review, S. aureus was the 
commonest etiology in the first study (1987–1989) and they recommended a 
combination of cloxacillin and gentamicin in place of penicillin or ampicillin with 
gentamicin. Then Klebsiella was the commonest aetiology in the second study (1991–
1992) and the second recommendation was a combination of cefotaxime and 
gentamicin for empirical treatment of neonatal sepsis. The recommendation from the 
first study was adopted and implemented, and subsequently so was the second 
recommendation. The authors recommended the same empiric antibiotic regimen 
after their retrospective review in 2006-2007 as their second review (1991-1992) but 
thereafter, the treatment should be tailored to the antibiotic sensitivity report obtained 
from the laboratory.(19) 
 
CONCLUSION 
 
As evident from the literature reviewed, the organisms responsible for neonatal sepsis 
differ across countries,(12) however there are few studies that document changing 
aetiology within a specific unit. Contaminated blood cultures may affect true sepsis 
profiles and has cost consequences to NICU's (34) globally and falsely encourages 
antibiotic overuse. Antibiotic sensitivity patterns also change continuously depending 
on pattern of organisms cultured. Resistant organisms are a growing clinical concern 
and periodically surveying the causes of sepsis and their antibiotic sensitivity patterns 
is pivotal in the design of effective infection control programmes and in guiding 
empirical antibiotic therapy.(3, 15, 16) These data illustrate the need for antibiotic 
stewardship, infection control measures and ongoing surveillance. More research is 
needed in this field. 
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CHAPTER TWO – PUBLICATION READY MANUSCRIPT 
 
 
ABSTRACT 
 
Background: Neonatal infection is an important cause of morbidity and mortality in 
babies. The causative pathogens and their antibiotic susceptibility patterns should be 
monitored so that treatment regimens can be adjusted to maintain efficacy and avoid 
selection of resistant organisms. 
Objectives: To compare the incidence of culture positive neonatal sepsis; and to 
describe the pathogens and antibiotic resistance profiles for significant organisms 
over a 15-year period in a tertiary nursery in Cape Town. 
Methods: Retrospective blood culture data for 12 months were collected at three time 
points over a 15-year period. Blood cultures from 2004, 2013 and 2017 were 
analysed. All neonates with growth on blood cultures were included.  
Results: During 2004 a total of 817 (43.3% of total admissions) blood cultures were 
taken, 171 (9.1% of total admissions) were culture positive. The most common 
invasive organisms were Klebsiella pneumoniae (31.8% of invasive organisms), 
S.aureus (26.1%) and enterococcus species (7.3%). There were 102 contaminants 
(12.5% of total cultures) of which 7.8% were due to Coagulase-negative 
Staphylococcus (CONS).  
In 2013 a total of 1070 (46.8% of total admissions) blood cultures were taken, 124 
(5.4% of total admissions) were culture positive. Common invasive organisms were 
Klebsiella pneumoniae (53.8% of invasive organisms), E. coli (12.8%) and S. aureus 
(10.3%). Forty-six blood cultures were deemed contaminated (4.3% of all cultures) 
and of these 2.1% were due to CONS. 
In 2017, there were 581 blood cultures taken (26.5% of total admissions), 56 were 
culture positive (2.6% of total admissions). Commonly occurring invasive organisms 
were Klebsiella pneumoniae (32.4% of invasive organisms), Group B streptococcus 
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(16.2%) and Acinetobacter (13.5%). Twenty-nine blood cultures were considered 
contaminated (5.6% of cultures) of which 1.7% were CONS. 
The gram-negative organisms showed an increasing resistance to penicillin, 
ampicillin and aminoglycosides but remained sensitive to carbapenems. 
Conclusions: The initial reduction in positive blood cultures from 2004 to 2013 was 
primarily due to the reduction of contaminants, probably reflecting improved blood 
sampling techniques. The large reduction in Gram-negative organisms from 2013 to 
2017 suggests improved infection control measures, but gram-negative organisms 
remained prominent in all three cohorts. Emergence of resistant organisms is 
concerning and in keeping with other nurseries worldwide. These data illustrate the 
need for antibiotic stewardship, infection control measures and ongoing surveillance. 
 
Introduction 
According to the World Health Organisation (WHO), an estimated 5 million neonates 
die annually with approximately 1.6 million deaths in developing countries due to 
neonatal sepsis[1-3]. Neonates are vulnerable to infection, partly due to an immature 
immune system that is unable to respond adequately to infection. They exhibit both 
qualitative and quantitative defects in their complement system and low 
concentrations of immunoglobulins[4]. Compounding this, their immature skin forms a 
weak barrier against the environment and admission to hospital may involve invasive 
procedures which can place them at risk for acquiring infection.  
Neonatal sepsis is defined as a clinical syndrome in an infant aged 28 days or 
younger, manifested by systemic signs of infection and isolation of a bacterial 
pathogen from the bloodstream[5]. It may be further categorised as early-onset sepsis 
(EOS), occurring within the first 72 hours, or late-onset (LOS) sepsis, occurring after 
72 hours[4]. EOS is  infection acquired before or during delivery with 85% presenting 
within the first 24 hours[5]. LOS is associated with Hospital-acquired Infections 
(HAIs) or community acquired sepsis. More resistant organisms are expected from 
hospital-acquired late sepsis when compared to vertically transmitted or community 
acquired sepsis [6].  It has been documented in previous studies that hospital-acquired 
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neonatal infections  are 3–20 times higher in resource-poor than resource-rich 
countries[7].  
Gram positive organisms such as Group B Streptococcus (GBS) are a major cause of 
neonatal sepsis (EOS and LOS), first identified in the early 1960’s. The neonatal 
infection rate of GBS through vertical transmission ranges from 1-2/1000 live births 
and maternal prophylaxis against this pathogen has been implemented in some 
countries around the world since the 1990’s. [8]. Coagulase negative staphylococcal  
(CONS) can be implicated in both early and late neonatal sepsis – there are no 
definitive guidelines on classification of CONS as a pathogen or a contaminant but it 
may be considered a contaminant in the absence of central lines or other 
instrumentation [9] [10]. Gram negative organisms are also emerging as a cause of 
serious neonatal infections. E.coli, Klebsiella pneumoniae and Pseudomonas 
Aeruginosa are such organisms found to cause both early and late sepsis.[11, 12] No 
prophylaxis or screening exists for these organisms, therefore prompt identification 
and treatment is necessary.  
Overuse of broad-spectrum antibiotics is what drives emergence of resistance. 
Surveillance and antibiotic stewardship help prevent inappropriate antibiotic use.  In 
South Africa the surveillance programme as outlined by the department of health 
focuses on the ESKAPE pathogens (Enterococcus faecium/faecalis, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, 
and Escherichia coli species) and Candida within blood cultures only, as they are the 
leading causes of nosocomial infections throughout the world[13].  
The Groote Schuur Hospital (GSH) Neonatal Unit, with its 75-bed capacity, admits 
more than 2000 neonates per year with over 500 of these being classified as Very 
Low Birth Weight infants (infants below 1500g). The nursery is a tertiary referral 
centre for the Metro West geographical service area of the Western Cape, South 
Africa. The GSH Neonatal Unit policy for suspected sepsis is based on a consistent 
approach to antibiotic usage to provide optimal cover while being mindful about 
limiting the emergence of resistant micro-organisms[14]. Empiric antibiotic usage is 
determined by local epidemiological and susceptibility data. Periodically surveying 
the causes of sepsis and their antibiotic sensitivity patterns is pivotal in the design of 
effective infection control programmes and in guiding empirical antibiotic therapy [2, 
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15, 16]. We therefore sought to describe the changes in cultured organisms and their 
antibiotic sensitivities, over an extended period in our nursery.  
 
Objectives 
The objectives of this study were: 
1. To compare the incidence of culture positive neonatal sepsis over a 15-year 
period in our tertiary neonatal unit 
2. To compare the pathogens and antibiotic resistance profiles over the same 
period. 
Methods 
Blood culture and sensitivity data were retrospectively collected from the National 
Health Laboratory Service (NHLS) and ward databases. For interval surveillance 
purposes, three time periods were included for comparison: 2004, 2013 and 2017. 
These periods were chosen because the first complete database was established in 
2004; 2013 reflects a quality improvement project undertaken to determine changing 
sensitivities and 2017 was the most current year of a complete set of data. Due to the 
nature of the database, only blood cultures that were flagged positive were included – 
those flagged positive from cerebrospinal fluid, pleural or ascitic fluid, pus swabs and 
other tissue cultures were not evaluated.  
A blood culture is considered the gold standard for sepsis diagnosis. At the GSH 
neonatal unit, absolute indicators for blood culture and empiric antibiotic treatment 
include maternal invasive bacterial infection requiring antibiotics (suspected or 
confirmed), confirmed or suspected infection in twin, respiratory distress starting 
more than 4 hours after birth, mechanical ventilation in a term baby, seizures and 
signs of shock. Relative indications include prelabour ROM, GBS in previous baby, 
maternal fever greater than 38 degrees, apnoea, altered behaviour/tone, but empiric 
antibiotics would only be initiated if more than one of the above were present[14]. 
Positive blood cultures were further scrutinised to determine whether they were likely 
contaminants or likely invasive organisms. With regards to invasive organisms, it is 
important to note that the GSH maternity department does not routinely do GBS 
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screening. Organisms that were considered to be contaminants were: Coagulase 
Negative Staphylococcus (CONS) and less common organisms including 
Corynebacterium, Morganella, Bacillus cereus, Staphylococcal epidermidis and 
Streptococcus (viridans, sanguinis, mitis, bovis, salivarus). These were considered 
contaminants because central lines are not routinely inserted for infants being 
managed at GSH nursery and this approach did not differ during the 15-year time 
period. 
Data were analysed with Stata software version 12 (Statacorp, College Station, Tex., 
USA). Proportions were compared using the chi-squared or Fisher-exact test 
depending on expected frequencies. Statistical significance was set at p<0.05. Ethical 
approval for the study was obtained from the University of Cape Town Faculty of 
Health Sciences Human Research Ethics Committee. 
 
Results 
The frequencies of positive blood cultures and organisms cultured for the three time 
periods are shown in Table 1. The number of admissions increased from 2004 to 2013 
and was similar thereafter. The total number of blood cultures taken per number of 
admissions decreased from 43.3 % in 2004 to 26.5 % in 2017 - a progressive and 
highly significant reduction (p<0.001).  The proportion of positive blood cultures also 
decreased progressively and significantly from 9.1% to 2.6%. The decrease in 
positive cultures was reflected both in the contaminants (12.5% to 5.6%) and the 
invasive organisms (3.7% to 1.7%). The most frequent contaminants were CONS and 
these species also showed a sustained reduction. 
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Table 1: Frequencies of positive cultures and organisms cultured 
 2004 2013 2017 p-value 
Admissions  1887 2285 2190 - 
Blood cultures taken n (% of admissions) 817 (43.3) 1070 (46.8) * 581(26.5) † < 0.001 
Positive cultures n (% of admissions) 171 (9.1) 124 (5.4) * 56 (2.6) † < 0.001 
Culture positivity rate (% of cultures taken) 21% 12%* 10% < 0.001 
Invasive organisms n (% of admissions) 69 (3.7) 78 (3.4) 37 (1.7) † < 0.001 
Contaminants n (% of cultures) 102 (12.5) 46 (4.3) * 29 (5.6) < 0.001 
CONS n (% of cultures) 64 (7.8) 22 (2.1) * 10 (1.7) < 0.001 
Acinetobacter n (% of invasive organisms) 2 (2.9) 0 5 (13.5) † 0.002 
Enterobacter species n  
(% of invasive organisms) 
 4 (5.8) 2 (2.6) 1 (2.7) 0.549 
Enterococcus species n  
(% of invasive organisms) 
5 (7.3) 6 (7.7) 0  0.228 
E. Coli n (% of invasive organisms) 9 (13) 10 (12.8) 4 (10.8) 0.681 
GBS n (% of invasive organisms) 3 (4.3) 4 (5.1) 6 (16.2) 0.056 
H. Influenzae n (% of invasive organisms) 2 (2.9) 0 0  0.185 
Klebsiella n (% of invasive organisms) 22 (31.8) 42 (53.8) * 12 (32.4) † 0.012 
Pseudomonas n (% of invasive organisms) 2 (2.9) 1 (1.3) 2 (5.4) 0.443 
Staph aureus n (% of invasive organisms) 18 (26.1) 8 (10.3) * 0 † 0.001 
Serratia n (% of invasive organisms) 3 (4.3) 3 (3.8) 1 (2.7) 0.914 
Listeria n (% of invasive organisms) 0 1 (1.3) 2 (5.4) 0.106 
Sternotrophomonas n  
(% of invasive organisms) 
0 1 (1.3) 1 (2.7) 0.431 
Candida sp n (% of invasive organisms) 0 3 (3.8) 3 (8.1) 0.077 
* p < 0.05 compared to 2004; † p < 0.05 compared to 2013 
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There were 13 different invasive organisms identified in the three cohorts. The most 
common was Klebsiella pneumonia. The frequencies of the six most common 
organisms are shown in Figure 1. There was a significant increase in Klebsiella 
pneumonia from 2004 to 2013; and a subsequent decrease from 2013 to 2017 
(p<0.05), although in 2017 the frequency was the same as 2004. Only S. aureus had a 
significant reduction at each time point (p<0.05). Over the three cohorts, methicillin-
resistant staphylococcus aureus (MRSA) was only cultured once in 2013. Of note, 
previously almost non-existent Acinetobacter baumannii emerged as a significant 
organism in 2017 (p<0.05). In 2017, all cultured Acinetobacter showed resistance to 
carbapenems (whereas they were sensitive in 2004). The frequencies of GBS 
progressively increased, but the differences were not significant.  
Figure 1: Most common invasive organsisms as a percentage of all invasive 
organisms 
 
The antibiotic sensitivities of invasive organisms were variable. The Klebsiella 
pneumonia group was the largest group and hence the most useful to consider as a 
benchmark. The variation in antibiotic sensitivity for this group is shown in Figure 2.  
Comparatively, the Klebsiella pneumonia organisms cultured in later cohorts of 2013 
and 2017, showed an overall resistance to Bactrim, Cephalosporins, Gentamycin and 
Co-amoxiclav – ESBL species dominated with more than 90% resistance to 
Cefepime, Ceftazidime and Cefotaxime during these two time periods. Most 
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organisims remained sensitive to Amikacin, Piptazobactam and Ciprofloxacin. All 
organisms remained sensitive to Meropenem. 
Figure 2: Frequencies of antibiotic resistance for Klebsiella Pneumonia 
 
 
Discussion 
This study shows a progressive decrease in number of blood cultures taken and 
organisms cultured during the 15-year period; but also, emergence of resistant 
organisms. The reduction in blood cultures taken may reflect application of more 
stringent indications for culture. The clinical signs for neonatal sepsis are often 
nonspecific and in the GSH Neonatal Unit neonates who meet suspected sepsis 
criteria are screened.    
Antibiotic resistance, mainly driven by antibiotic misuse and overuse, is a global 
phenomenon and across the world and all medical units (including neonatal) are 
becoming wary of this multi resistant organism problem. While awaiting the 
development of new antibiotics, we must be careful against multidrug resistant Gram 
negative bacteria, highlighting the need to preserve what we have and use it 
appropriately[17]. 
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South African neonatal unit (not tertiary), their invasive organisms cultured was far 
greater in number  than any of our cohorts but this is likely because they considered 
CONS as an invasive organism (132 invasive organisms vs 69 for GSH)[12] . Our total 
number of positive blood cultures was lower (and decreased  in our latter cohorts) as 
compared to a tertiary neonatal unit in South Africa as documented in E. Ballot et 
al[15] (171-124-56 vs 246). We suspect the reason for our much lower positive yield 
was due to our focussed screening protocols and because we considered CONS a 
contaminant in our unit. 
The reduction in blood cultures taken may alternatively reflect improved infection 
control measures and a decreased frequency of HAIs. The infection control measures 
that were introduced included written policies prioritising and reinforcing hand 
washing and a ‘bare-below-elbows approach’, establishing a uniform blood culture 
technique, antibiotic stewardship and insertion and management of central lines 
according to a standardised protocol [18].  
Although the frequency of both invasive organisms and contaminants were reduced 
during the 15-year period, the greatest reduction in positive cultures was seen in the 
number of contaminants. The decrease in invasive organisms may be due to improved 
infection control measures since the number of infants admitted from other hospitals 
increased during this time so it is less likely due to the demographic of the admitted 
infants.  
CONS cultured far less  in our unit over our three cohorts than what was seen by 
Lebea et al. (23.7%) in their tertiary neonatal unit review[16]. Particularly in our later 
cohorts (2013 and 2017), the reduction in contamination rates during the study was 
probably due to more stringent blood-taking protocols and blood culture bundles that 
were implemented to ensure all cultures taken were done in sterile manner. By 
continually auditing how staff take samples and ensuring that we screen only those 
neonates with suspected sepsis, we hope this will aid in further decreasing 
contamination in our unit in the future. By continuing to implement the above 
measures and by continuing to educate our staff as demonstrated by Raban et al 
within our unit, we have continued to demonstrate our earlier findings in decreasing 
contamination [18].  
Unlike the low GBS rates documented by Lebea et al (1.3%) [16] and F. Motara et al 
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(1.5%)[12], GBS remains of concern in our unit. The trend towards increased 
frequency of GBS infection stresses the need for maternal screening and intrapartum 
prophylaxis.  We agree with Koenig et al that despite being in an era of screening, 
GBS continues to be an important cause of sepsis, and thus remains a significant 
public health issue. Measures that augment its diagnosis and prevention are important 
to prevent neonatal morbidity and mortality.[8] 
Early and efficient diagnosis of neonatal sepsis remains nuanced as clinical 
manifestations vary greatly. This necessitates the use of an empiric antibiotic therapy 
approach based upon the suspicion of sepsis [12].  While evidence is lacking, the 
choice of antibiotics for suspected neonatal sepsis may be guided by the spectrum of 
organisms from surveillance of cultures, for example the prevalence of Group B 
Streptococcus and Gram negative organisms [19]. 
It is important to monitor changing organisms within a neonatal unit with emerging 
new pathogens. The emergence of resistant organisms is of concern in any unit 
worldwide. MRSA is known to be an important pathogen in the NICU setting. In our 
study however, the nursery is relatively spared but it is a well documented threat we 
must continue to monitor[20].  Acinetobacter baumanii showed a statistically 
significant emergence in 2017 (p<0.05) compared to 2013 and 2004 cohorts.  
Acinetobacter was also completely resistant to carbapenems in 2017 as compared to 
2004. This resistance pattern has been shown in other institutes [16, 21].  It is prudent to 
continue monitoring for highly resistant organisms to effectively manage the 
vulnerable population we manage. The organisms responsible for neonatal sepsis 
differ across nurseries[22]. Surveillance is critical because one organism may over time 
replace another as the leading cause of neonatal sepsis in a particular nursery or 
geographical region. This is further compounded by the fact that local drug resistance 
profiles change over time, thereby complicating treatment regimens [12]. 
At GSH Neonatal Unit, penicillin or ampicillin (if penicillin is out of stock) and 
gentamycin are our first line empirical antibiotics of choice for suspected sepsis and 
have been so over all three time periods. For suspected LOS in 2004 we empirically 
used penicillin/ampicillin and amikacin. Data from the 2013 cohort resulted in a 
change following the emergence of resistant organisms to the two antibiotics 
particularly the aminoglycosides. All infants that develop suspected nosocomial 
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sepsis are now commenced on a carbapenem (meropenem) to which all organisms 
remain fully sensitive. Once the organism is identified and the sensitivity pattern is 
known, antibiotics are downscaled appropriately. At GSH Neonatal unit, probiotics 
were not used during the 15 year period under review. 
Limitations and Strengths 
The study has limitations. It is retrospective from a single unit and the data was 
limited to what was available on the NHLS database. There was no review of files to 
obtain demographic and further clinical details, however the number of admissions 
has remained relatively stable over the time periods studied. Due to the nature of the 
data set, no comment could be made about previous unit protocols nor could we 
comment on the timing of infection control measures implemented. The strengths of 
the study are that it refers to complete blood culture data over three separate time 
intervals and is based in a unit with uniform, protocol-based management principles. 
 
Conclusion 
This study provides insight into the evolving pathogens and guides the appropriate 
antibiotics for empiric therapy in our nursery. The initial reduction in positive blood 
cultures from 2004 to 2013 was primarily due to the reduction of contaminants, 
probably reflecting improved blood sampling techniques and unit protocols. The large 
reduction in Gram-negative organisms from 2013 to 2017 indicates improved 
infection control measures, but gram-negative organisms remained prominent in all 
three cohorts. Emergence of resistant organisms is concerning and in keeping with 
other nurseries worldwide. These data illustrate the need for antibiotic stewardship, 
infection control measures and ongoing surveillance. 
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General article format/layout 
Accepted manuscripts that are not in the correct format specified in these guidelines 
will be returned to the author(s) for correction, which will delay publication. 
General: 
 Manuscripts must be written in UK English. 
 The manuscript must be in Microsoft Word or RTF document format. Text must be 
single-spaced, in 12-point Times New Roman font, and contain no 
unnecessary formatting (such as text in boxes). 
 Please make your article concise, even if it is below the word limit. 
 Qualifications, full affiliation (department, school/faculty, institution, city, country) 
and contact details of ALL authors must be provided in the manuscript and in 
the online submission process. 
 Abbreviations should be spelt out when first used and thereafter used consistently, 
e.g. 'intravenous (IV)' or 'Department of Health (DoH)'. 
 Include sections on Acknowledgements, Conflict of Interest, Author Contributions 
and Funding sources. If none is applicable, please state ‘none’.  
 Scientific measurements must be expressed in SI units except: blood pressure 
(mmHg) and haemoglobin (g/dL). 
 Litres is denoted with an uppercase L e.g. 'mL' for millilitres). 
 Units should be preceded by a space (except for % and ºC), e.g. '40 kg' and '20 cm' 
but '50%' and '19ºC'. 
 Please be sure to insert proper symbols e.g. µ not u for micro, a not a for alpha, b 
not B for beta, etc. 
 Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160. 
 Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
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 Round brackets (parentheses) should be used, as opposed to square brackets, which 
are reserved for denoting concentrations or insertions in direct quotes. 
 If you wish material to be in a box, simply indicate this in the text. You may use the 
table format –this is the only exception. Please DO NOT use fill, format lines 
and so on. 
  
SAMJ is a generalist medical journal, therefore for articles covering genetics, it is the 
responsibility of authors to apply the following: 
- Please ensure that all genes are in italics, and proteins/enzymes/hormones are not. 
- Ensure that all genes are presented in the correct case e.g. TP53 not Tp53. 
**NB: Copyeditors cannot be expected to pick up and correct errors wrt the above, 
although they will raise queries where concerned. 
- Define all genes, proteins and related shorthand terms at first mention, e.g. 
‘188del11’ can be glossed as ‘an 11 bp deletion at nucleotide 188.’ 
- Use the latest approved gene or protein symbol as appropriate: 
 Human Gene Mapping Workshop (HGMW): genetic notations and symbols 
 HUGO Gene Nomenclature Committee: approved gene symbols and nomenclature 
 OMIM: Online Mendelian Inheritance in Man (MIM) nomenclature and 
instructions 
 Bennet et al. Standardized human pedigree nomenclature: Update and assessment 
of the recommendations of the National Society of Genetic Counselors. J 
Genet Counsel 2008;17:424-433: standard human pedigree nomenclature. 
 
Preparation notes by article type 
Research 
Guideline word limit: 4 000 words 
Research articles describe the background, methods, results and conclusions of an 
original research study. The article should contain the following sections: 
introduction, methods, results, discussion and conclusion, and should include a 
structured abstract (see below). The introduction should be concise – no more than 
three paragraphs – on the background to the research question, and must include 
references to other relevant published studies that clearly lay out the rationale for 
conducting the study. Some common reasons for conducting a study are: to fill a gap 
in the literature, a logical extension of previous work, or to answer an important 
clinical question. If other papers related to the same study have been published 
previously, please make sure to refer to them specifically. Describe the study methods 
in as much detail as possible so that others would be able to replicate the study should 
they need to. Results should describe the study sample as well as the findings from 
the study itself, but all interpretation of findings must be kept in the discussion 
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section, which should consider primary outcomes first before any secondary or 
tertiary findings or post-hoc analyses. The conclusion should briefly summarise the 
main message of the paper and provide recommendations for further study. 
Select figures and tables for your paper carefully and sparingly. Use only those 
figures that provided added value to the paper, over and above what is written in the 
text. 
Do not replicate data in tables and in text . 
Structured abstract 
• This should be 250-400 words, with the following recommended headings: 
◦ Background: why the study is being done and how it relates to other 
published work. 
◦ Objectives: what the study intends to find out 
◦ Methods: must include study design, number of participants, description of 
the intervention, primary and secondary outcomes, any specific 
analyses that were done on the data. 
◦ Results: first sentence must be brief population and sample description; 
outline the results according to the methods described. Primary 
outcomes must be described first, even if they are not the most 
significant findings of the study. 
◦ Conclusion: must be supported by the data, include recommendations for 
further study/actions. 
• Please ensure that the structured abstract is complete, accurate and clear and has 
been approved by all authors. 
• Do not include any references in the abstracts. 
  
Main article 
All articles are to include the following main sections:  
Introduction/Background, Methods, Results, Discussion, Conclusions. 
 
The following are additional heading or section options that may appear within these: 
• Objectives (within Introduction/Background): a clear statement of the main aim of 
the study and the major hypothesis tested or research question posed 
• Design (within Methods): including factors such as prospective, randomisation, 
blinding, placebo control, case control, crossover, criterion standards for 
diagnostic tests, etc. 
• Setting (within Methods): level of care, e.g. primary, secondary, number of 
participating centres. 
• Participants (instead of patients or subjects; within Methods): numbers entering and 
completing the study, sex, age and any other biological, behavioural, social or 
cultural factors (e.g. smoking status, socioeconomic group, educational 
attainment, co-existing disease indicators, etc)that may have an impact on the 
study results. Clearly define how participants were enrolled, and describe 
selection and exclusion criteria. 
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• Interventions (within Methods): what, how, when and for how long. Typically for 
randomised controlled trials, crossover trials, and before and after studies. 
• Main outcome measures (within Methods): those as planned in the protocol, and 
those ultimately measured. Explain differences, if any. 
  
Results 
• Start with description of the population and sample. Include key characteristics of 
comparison groups. 
• Main results with (for quantitative studies) 95% confidence intervals and, where 
appropriate, the exact level of statistical significance and the number need to 
treat/harm. Whenever possible, state absolute rather than relative risks. 
• Do not replicate data in tables and in text. 
• If presenting mean and standard deviations, specify this clearly. Our house style is 
to present this as follows: 
• E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for 
mean (SD). 
• Leave interpretation to the Discussion section. The Results section should just 
report the findings as per the Methods section. 
  
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-
headings are not needed: 
• Statement of principal findings 
• Strengths and weaknesses of the study 
• Contribution to the body of knowledge 
• Strengths and weaknesses in relation to other studies 
• The meaning of the study – e.g. what this study means to clinicians and 
policymakers 
• Unanswered questions and recommendations for future research 
  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include 
primary conclusions and their implications, suggesting areas for further research if 
appropriate. Do not go beyond the data in the article. 
  
Illustrations/photos/scans 
• If illustrations submitted have been published elsewhere, the author(s) should 
provide 
consent to republication obtained from the copyright holder. 
• Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 
1)'. 
• Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in 
full). 
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• All images must be of high enough resolution/quality for print. 
• All illustrations (graphs, diagrams, charts, etc.) must be in PDF or jpeg form. 
• Ensure all graph axes are labelled appropriately, with a heading/description and 
units (as necessary) indicated. Do not include decimal places if not necessary 
e.g. 0; 1.0; 2.0; 3.0; 4.0 etc. 
• Scans/photos showing a specific feature e.g. Intermediate magnification 
micrograph of a low malignant potential (LMP) mucinous ovarian tumour. 
(H&E stain). –include an arrow to show the tumour. 
• Each image must be attached individually as a 'supplementary file' upon submission 
(not solely embedded in the accompanying manuscript) and named Fig. 1, Fig. 
2, etc. 
  
Tables 
 Tables should be constructed carefully and simply for intelligible data 
representation. Unnecessarily complicated tables are strongly discouraged. 
 Large tables will generally not be accepted for publication in their entirety. Please 
consider shortening and using the text to highlight specific important sections, 
or offer a large table as an addendum to the publication, but available in full 
on request from the author 
 Embed/include each table in the manuscript Word file - do not provide separately 
as supplementary files. 
 Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to 
consecutively in the text. 
 Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable. 
 Ensure each table has a concise title and column headings, and include units where 
necessary. 
 Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § 
¶ || then ** †† ‡‡ etc. 
  
Do not: Use [Enter] within a row to make ‘new rows’: 
Rather: 
Each row of data must have its own proper row. 
Do not: use separate columns for n and %: 
Rather: 
Combine into one column, n (%): 
Do not: have overlapping categories, e.g.: 
Rather: 
Use <> symbols or numbers that don’t overlap: 
 
References 
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NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. Reference lists must be generated manually and not with the use of 
reference manager software. Endnotes must not be used. 
 Authors must verify references from original sources.
 Citations should be inserted in the text as superscript numbers between square
brackets, e.g. These regulations are endorsed by the World Health 
Organization,[2] and others.[3,4-6] 

 All references should be listed at the end of the article in numerical order of 
appearance in the Vancouver style (not alphabetical order). 
 Approved abbreviations of journal titles must be used; see the List of Journals in
Index Medicus. 
 Names and initials of all authors should be given; if there are more than six authors,
the first three names should be given followed by et al. 
 Volume and issue numbers should be given.
 First and last page, in full, should be given e.g.: 1215-1217 not 1215-17.
 Wherever possible, references must be accompanied by a digital object identifier
(DOI) link). Authors are encouraged to use the DOI lookup service offered by 
CrossRef: 
◦ On the Crossref homepage, paste the article title into the ‘Metadata search’
box. 
◦ Look for the correct, matching article in the list of results.
◦ Click Actions > Cite
◦ Alongside 'url =' copy the URL between { }.
◦ Provide as follows, e.g.: https://doi.org/10.7196/07294.937.98x
• Other references (e.g. reports) should follow the same format: Author(s). Title.
Publisher place: Publisher name, year; pages. 
• Cited manuscripts that have been accepted but not yet published can be included as
references followed by '(in press)'. 
• Unpublished observations and personal communications in the text must not appear
in the reference list. The full name of the source person must be provided for 
personal communications e.g. '...(Prof. Michael Jones, personal 
communication)'. 
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4. Principal Investigator’s acknowledgement of responsibility
HREC office use only (FWA00001637; IRB00001938) 
This serves as acknowledgement of a protocol deviation as described below. 
Chairperson of the HREC signature Date 
Principal Investigator to complete the following: 
1. Protocol information
Date 
(when submitting this form) 
27/02/2019 
HREC REF Number 164/2017 
Project Title Neonatal sepsis and antibiotic sensitivity patterns at a south african tertiary 
nursery – evolution over a 15year period 
Protocol number 
(if applicable) 
Principal Investigator Prof M.C Harrison / Student – Dr Nayestha Naidoo 
Department / Office 
Internal Mail Address 
m.harrison@uct.ac.za
2. Protocol deviation description
Please describe the deviation below, including the reason why the deviation occurred. 
Ethics has expired as the study took longer than anticipated to gather information required 
3. Follow-up actions
3.1 Please describe any follow-up action(s) taken or planned as a result of this deviation e.g. DSMB reporting, 
report to sponsor, informing participants. 
3.2 Please describe what action(s) have or will be taken to prevent similar deviations in future. 
Information is now completed and write up is underway. Timeline to submission is within the next few weeks. 
This signature indicates the PI has reviewed the deviation, taken appropriate follow-up action and implemented 
or plans to implement preventative steps where possible. 
Signature of PI Date 4/03/2019 
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